Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 13.4% on Thursday . The company traded as high as GBX 10.80 and last traded at GBX 10.50. 7,242,426 shares traded hands during trading, a decline of 10% from the average session volume of 8,073,004 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Price Performance
The stock has a market capitalization of £55.80 million, a P/E ratio of -12.47 and a beta of 1.53. The firm has a 50 day moving average of GBX 11.08 and a 200-day moving average of GBX 5.47.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Rare Earth Stocks: The Truce That Isn’t a Truce
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- How to Invest in the FAANG Stocks
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
